Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
As first-line treatment of patients with unresectable or metastatic mirosatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancer
Therapeutic area
Oncology